CD70


Also found in: Wikipedia.

CD70

a type II transmembrane protein present on activated B cells and some activated T cells; enhances activation of T cells; expressed in Reed-Sternberg cells, some lymphomas, and monocyte lineage-derived tumors.
Mentioned in ?
References in periodicals archive ?
ARGX-110 is a first-in-class monoclonal antibody potently blocking CD70 induced tumor proliferation and tumor escape from immune surveillance.
Chapter 7focuses on novel inhibitors such as IDO-1, IDO-2, KIR, OX40, CD70, LAG-3 and more.
SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company's proprietary technology.
In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody(TM) program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors.
Preclinical data were presented at AACR showing that SGN-75, an ADC targeting CD70, induces potent cell-killing activity by releasing its payload, cysteine-mcMMAF, upon degradation of the antibody inside tumor cells.
In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody (TM) program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors, as well as in autoimmunity.
arGEN-X' most advanced program is ARGX-110, a fully human antibody with unprecedented neutralization potency for CD70, a compelling immunomodulatory target for the treatment of cancer and autoimmunity.
enhanced Antibody Dependent Cellular Cytotoxicity (ADCC) of ARGX-110 drives the selective destruction of CD70 positive tumor cells.
In November 2012, arGEN-X filed a first CTA for ARGX-110, its most advanced SIMPLE Antibody program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors, as well as in autoimmunity.
Data presented at AACR demonstrate CD70 expression on a variety of solid tumors, including pancreatic, larynx/pharynx, ovarian, skin, lung and colon cancer.
IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.
The study offers a comprehensive view of the emerging market of CTLA-4, PD-1, PD-L1 and several novel immune checkpoint inhibitors (IDO-1, IDO-2, KIR, OX40, CD70, LAG-3 and more).